PDCD1 and non-small cell lung carcinoma: Programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) antibodies have demonstrated impressive results in the treatment of patients with metastatic NSCLC without targetable mutations [1].